A novel biomarker panel for irritable bowel syndrome and the application in the general population

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mujagic, Zlatan ^a,b   Tigchelaar, Ettje F ^a,c   Zhernakova, Alexandra ^a,c   Ludwig, Thomas ^a,d   Ramiro Garcia, Javier ^a,e   Baranska, Agnieszka ^a,f   Swertz, Morris A ^a,c   Masclee, Ad A M ^b   Wijmenga, Cisca ^a,c   Van Schooten, Frederik J ^f   Smolinska, Agnieszka ^a,f   Jonkers, Daisy M A E ^a,b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d DANONE NUTRICIA RESEARCH   (Netherlands)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; IRRITABLE COLON; MALE; MASS SCREENING; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ADULT; AREA UNDER CURVE; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MASS SCREENING; MIDDLE AGED; ROC CURVE; YOUNG ADULT;

EID: 84974588700     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26420     Document Type: Article

References (48)

1. Bischoff, S. C. 'Gut health': a new objective in medicine? BMC Med 9, 24, doi: 10.1186/1741-7015-9-24 (2011).
2. Canavan, C., West, J. & Card, T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 6, 71-80, doi: 10.2147/CLEP.S40245 (2014).
3. Magro, F. et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7, 827-851, doi: 10.1016/j. crohns.2013.06.001 (2013).
4. Ludidi, S. et al. Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil 26, 1104-1111, doi: 10.1111/nmo.12365 (2014).
5. Corsetti, M., Van Oudenhove, L. & Tack, J. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 26, 1669-1676, doi: 10.1111/nmo.12475 (2014).
6. Camilleri, M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther 42, 818-828, doi: 10.1111/apt.13351 (2015).
7. Spiegel, B. M., Farid, M., Esrailian, E., Talley, J. & Chang, L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 105, 848-858, doi: 10.1038/ajg.2010.47 (2010).
8. Sood, R., Gracie, D. J., Law, G. R. & Ford, A. C. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 42, 491-503, doi: 10.1111/apt.13283 (2015).
9. Sood, R. & Ford, A. C. Combining biomarkers in irritable bowel syndrome: A forward step towards making a positive diagnosis and directing therapy? Gastroenterology, doi: 10.1053/j.gastro.2015.04.032 (2015).
10. Lembo, A. J. et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 29, 834-842, doi: 10.1111/j.1365-2036.2009.03975.x (2009).
11. Jones, M. P. et al. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 39, 426-437, doi: 10.1111/apt.12608 (2014).
12. Camilleri, M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367, 1626-1635, doi: 10.1056/NEJMra1207068 (2012).
13. Mujagic, Z. et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 40, 288-297, doi: 10.1111/apt.12829 (2014).
14. Tigchelaar, E. F. et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open 5, e006772, doi: 10.1136/bmjopen-2014-006772 (2015).
15. Stolk, R. P. et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 23, 67-74, doi: 10.1007/s10654-007-9204-4 (2008).
16. Crenn, P., Messing, B. & Cynober, L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 27, 328-339, doi: 10.1016/j.clnu.2008.02.005 (2008).
17. Windmueller, H. G. & Spaeth, A. E. Source and fate of circulating citrulline. Am J Physiol 241, E473-480 (1981).
18. van Vliet, M. J. et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 53, 1188-1194, doi: 10.1002/pbc.22210 (2009).
19. Lutgens, L. C. et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 103, 191-199, doi: 10.1002/cncr.20733 (2005).
20. Bashashati, M. et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 26, 1036-1048, doi: 10.1111/nmo.12358 (2014).
21. O'Mahony, L. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551 (2005).
22. Dolwani, S., Metzner, M., Wassell, J. J., Yong, A. & Hawthorne, A. B. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 20, 615-621, doi: 10.1111/j.1365-2036.2004.02128.x (2004).
23. Ohman, L., Stridsberg, M., Isaksson, S., Jerlstad, P. & Simren, M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 107, 440-447, doi: 10.1038/ajg.2011.458 (2012).
24. Vora, P. et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 173, 5398-5405 (2004).
25. Langhorst, J. et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 104, 404-410, doi: 10.1038/ajg.2008.86 (2009).
26. Hamer, H. M. et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104-119, doi: 10.1111/j.1365-2036.2007.03562.x (2008).
27. Tana, C. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22, 512-519, e114-515, doi: 10.1111/j.1365-2982.2009.01427.x (2010).
28. Facer, P. et al. Chromogranin: a newly recognized marker for endocrine cells of the human gastrointestinal tract. Gastroenterology 89, 1366-1373 (1985).
29. Usellini, L. et al. Ultrastructural identification of human secretin cells by the immunogold technique. Their costorage of chromogranin A and serotonin. Histochemistry 94, 113-120 (1990).
30. El-Salhy, M., Lomholt-Beck, B. & Hausken, T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 45, 1435-1439, doi: 10.3109/00365521.2010.503965 (2010).
31. Garcia-Villalba, R. et al. Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J Sep Sci 35, 1906-1913, doi: 10.1002/jssc.201101121 (2012).
32. Farzi, A. et al. Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers. Brain Behav Immun, doi: 10.1016/j.bbi.2014.08.011 (2014).
33. Whelan, R. A. et al. A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol Ther 22, 1730-1740, doi: 10.1038/mt.2014.125 (2014).
34. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate-a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57, 289-300 (1995).
35. Schafer, J. L. Multiple imputation: a primer. Statistical Methods in Medical Research 8, 3-15 (1999).
36. Wold, S., Sjostrom, M. & Eriksson, L. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 58, 109-130, doi: 10.1016/S0169-7439(01)00155-1 (2001).
37. Guyon, I. A Scaling Law for the Validation-Set Training-Set Size Ratio. AT & T Bell Laboratories (1997).
38. Gidskehaug, L., Anderssen, E. & Alsberg, B. K. Cross model validated feature selection based on gene clusters. Chemometrics and Intelligent Laboratory Systems 84, 172-176, doi: 10.1016/j.chemolab.2006.05.008 (2006).
39. Esbensen, K. H. & Geladi, P. Principles of Proper Validation: use and abuse of re-sampling for validation. Journal of Chemometrics 24, 168-187 (2010).
40. Hardoon, D. R., Szedmak, S. & Shawe-Taylor, J. Canonical correlation analysis: An overview with application to learning methods. Neural Computation 16, 2639-2664, doi: 10.1162/0899766042321814 (2004).
41. Liu, Z. J. et al. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. European Journal of Immunology 31, 1550-1560, doi: 10.1002/1521-4141(200105)31:5 3.0.Co;2-3 (2001).
42. Vignali, D. A. A. & Kuchroo, V. K. IL-12 family cytokines: immunological playmakers. Nature Immunology 13, 722-728, doi: 10.1038/Ni.2366 (2012).
43. Zheng, H. et al. Resistance to Fever Induction and Impaired Acute-Phase Response in Interleukin-1-Beta-Deficient Mice. Immunity 3, 9-19, doi: 10.1016/1074-7613(95)90154-X (1995).
44. Dinarello, C. A. Immunological and Inflammatory Functions of the Interleukin-1 Family. Annual Review of Immunology 27, 519-550, doi: 10.1146/annurev.immunol.021908.132612 (2009).
45. Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813, 878-888, doi: 10.1016/j.bbamcr.2011.01.034 (2011).
46. Shah, E., Rezaie, A., Huang, L. & Pimentel, M. The Prevalence of Irritable Bowel Syndrome in Patients With Typical Symptoms Referred to the Gastroenterologist: A Systematic Review. Am. J. Gastroenterol. (suppl 1), S758 (2015).
47. Mujagic, Z. et al. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther, doi: 10.1111/apt.13378 (2015).
48. Ford, A. C. & Moayyedi, P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 32, 144-158, doi: 10.1111/j.1365-2036.2010.04328.x (2010)